Clinical Trial Update: Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC [Phase 2, Phase 3]

View source ↗

Summary

A neoadjuvant trial comparing Anti-PD-1 plus TP versus TPF in oral squamous cell carcinoma is ongoing (Phase 2/3) to evaluate pathological response.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Squamous Cell Carcinoma

Drugs mentioned

• Anti-PD-1
• TP
• TPF

Snippet

Sponsor: Shanghai Jiao Tong University School of Medicine | Conditions: Oral Squamous Cell Carcinoma, Neoadjvant Therapy | Phase 2, Phase 3 | Status: RECRUITING